article thumbnail

STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children

STAT

About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to a startup his designs for a powerful new type of therapy, called CAR-T, that would re-engineer a child’s own immune cells to target cancer. The deal proved be a mixed blessing. But it was never approved for childhood cancer. 

article thumbnail

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

pharmaphorum

Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. In a statement Sanofi said that the acquisition will give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty payments due under the 2017 agreement.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

article thumbnail

Key vaccine adjuvant biosynthesised

European Pharmaceutical Review

highlighted in the paper a key milestone achieved by the vaccine industry in 2017: “the first saponin adjuvant AS01 was approved for use in a human vaccine, the highly effective shingles vaccine Shingrix (produced by GSK).” “Our Martin et al. Our study opens unprecedented opportunities for bioengineering vaccine adjuvants.

article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells. However, 2017 saw the discontinuation of nabiximols from Phase III development in the US for cancer pain, due to lack of efficacy.

article thumbnail

Long-acting antibody demonstrates promising efficacy in infant RSV

European Pharmaceutical Review

Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.

Hospitals 122
article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin. The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies.